{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:20:10Z","timestamp":1794486010437,"version":"4.9.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41591-024-02988-7","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T06:02:44Z","timestamp":1719554564000},"page":"2121-2124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":195,"title":["Revised criteria for the diagnosis and staging of Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-622X","authenticated-orcid":false,"suffix":"Jr","given":"Clifford R.","family":"Jack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Buracchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4458-113X","authenticated-orcid":false,"given":"William","family":"Jagust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-3866","authenticated-orcid":false,"given":"Eric","family":"McDade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozioma C.","family":"Okonkwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2094","authenticated-orcid":false,"given":"Michael S.","family":"Rafii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Siemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1535-6133","authenticated-orcid":false,"given":"Reisa","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"2988_CR1","doi-asserted-by":"publisher","unstructured":"Jack, C. R. Jr. et al. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13859 (2024).","DOI":"10.1002\/alz.13859"},{"key":"2988_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Alzheimers Dement. 7, 280\u2013292 (2011).","journal-title":"Alzheimers Dement."},{"key":"2988_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack, C. R. Jr. et al. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"2988_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2988_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"2988_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson, O., Blennow, K., Zetterberg, H. & Dage, J. Nat. Aging 3, 506\u2013519 (2023).","journal-title":"Nat. Aging"},{"key":"2988_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman, B. T. et al. Alzheimers Dement. 8, 1\u201313 (2012).","journal-title":"Alzheimers Dement."},{"key":"2988_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark, C. M. et al. Lancet Neurol. 11, 669\u2013678 (2012).","journal-title":"Lancet Neurol."},{"key":"2988_CR9","unstructured":"PRNewswire https:\/\/go.nature.com\/3WcfHYH (4 May 2022)."},{"key":"2988_CR10","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze, S. et al. Brain 146, 1592\u20131601 (2023).","journal-title":"Brain"},{"key":"2988_CR11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy, N. R. et al. Nat. Med. 26, 398\u2013407 (2020).","journal-title":"Nat. Med."},{"key":"2988_CR12","doi-asserted-by":"publisher","first-page":"e075367","DOI":"10.1002\/alz.075367","volume":"19","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3, G. et al. Alzheimers Dement. 19, e075367 (2023).","journal-title":"Alzheimers Dement."},{"key":"2988_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JAD-201213","volume":"79","author":"TG Beach","year":"2021","unstructured":"Beach, T. G. & Malek-Ahmadi, M. J. Alzheimers Dis. 79, 389\u2013400 (2021).","journal-title":"J. Alzheimers Dis."},{"key":"2988_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody, R. S. et al. N. Engl. J. Med. 370, 311\u2013321 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2988_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/jir.12390","volume":"61","author":"M McCarron","year":"2017","unstructured":"McCarron, M. et al. J. Intellect. Disabil. Res. 61, 843\u2013852 (2017).","journal-title":"J. Intellect. Disabil. Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02988-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02988-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02988-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:10:56Z","timestamp":1724047856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02988-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2988"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-02988-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"assertion":[{"value":"28 June 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.R.J. is employed by Mayo Clinic; receives grant funding from the National Institutes of Health (NIH), the Alexander family professorship and the GHR Foundation; served on a data and safety monitoring board for Roche pro bono within the past 36 months with no payments to the individual or institution involved; and received funding from the Alzheimer\u2019s Association for travel and holds index funds. J.S.A. is employed by Takeda Pharmaceuticals and is a minor shareholder for the company; has a leadership or fiduciary role in the Clinical Trials on Alzheimer\u2019s Disease (CTAD) Task Force\u2014Clinical Meaningfulness and Optimizing Therapies, Alzheimer\u2019s Disease PACE Executive Steering Committee and UsAgainstAlzheimer\u2019s\u2014Clinical Meaningfulness Forum; is a former employee of Eli Lilly and Company and is a minor shareholder for the company. T.G.B. is employed by Banner Health; received grant funding from the NIH, Veterans Administration, State of Arizona, Life Molecular Imaging, Michael J. Fox Foundation for Parkinson\u2019s Research, Avid Radiopharmaceuticals\/Eli Lilly and Gates Foundation; received consulting fees from Aprinoia Therapeutics and Acadia Pharmaceuticals, and consulted unpaid for Biogen; received payment or honoraria from the World PD Coalition, Mayo Clinic Florida, Stanford University and the IOS Press-<i>Journal of Parkinson\u2019s Disease<\/i>; received support for attending meetings from the Alzheimer\u2019s Association, AD\/PD\/Kenes Group, Mayo Clinic Florida and the Universit\u00e4tsklinikum Hamburg-Eppendorf; and has a leadership or fiduciary role and stock options with Vivid Genomics. T.B. is employed by the US FDA and has no financial conflicts to disclose. B.D. is a consultant and received consulting fees for his role as an advisor for Arch Venture Partners, Cerveau Technologies, Epilepsy Foundation, F-PRIME Capital, Loulou Foundation and Michael J. Fox Foundation; held a past position of leadership or fiduciary role in the Virginia Neurological Society (past president) and Prothena (director); and holds stock options with Prothena. A.G. is employed by Novartis Pharma AG and has stock options in the company. O.H. is employed by Lund University; received grants or contracts from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche; and received consulting fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. O.H. is employed by Lund University; received research support to his institution from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare and Roche; received consultancy or speaker fees within the past 2 years from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. C.H. is employed by Denali Therapeutics and has stock options with the company; is a board director for Beam Therapeutics and NGM Therapeutics and has stock options with both companies. W.J. is employed by the University of California, Berkley; received grants or contracts paid to his institution from the US NIA, Roche\/Genentech, Alzheimer\u2019s Association and BrightFocus Foundation; received consulting fees from Biogen, Clario, Eisai, Lilly and Prothena; and has stock with Optoceutics and Molecular Medicine. E. McDade is employed by Washington University, St Louis, and received grant funding directly to his institution from NIA, Eli Lilly, Hoffmann-La Roche, Alzheimer\u2019s Association and GHR Foundation; received royalties for work on \u2018Methods of diagnosing AD with phosphorylation changes\u2019, which is licensed to C2N with royalties to himself and Washington University; received consulting fees from Alzamend (scientific advisory board member), Sanofi, AstraZeneca, Roche, Grifols, Merck and Sage; received payments from Neurology Live, Kaplan-Projects in Knowledge, and support for travel from Foundation Alzheimer, Alzheimer\u2019s Association and Eisai; has a patent planned, issued or pending on \u2018Methods of diagnosing Alzheimer\u2019s disease with phosphorylation changes\u2019; participated on a data safety monitoring board or advisory board for Alector and Eli Lilly, both roles for which he was paid; and has a leadership or fiduciary role in Alzamend (paid). J.L.M. is a full-time employee of H. Lundbeck A\/S. O.O. is employed by University of Wisconsin School of Medicine & Public Health and received support paid to his institution from the following grants: R01AG062167, R01AG077507, U19AG024904, U19AG078109, U19AG073153, R01AG066203, R01AG070028, R01AG027161 and RF1AG052324; received consulting fees from Mayo Clinic Rochester and IUPUI; holds a leadership or fiduciary role in the International Neuropsychological Society (board member); and previously held an advisory role for Society for Black Neuropsychology. L.P. is employed by the University of Miami and the University of Modena and Reggio Emilia and has no financial conflicts to disclose; in unrelated areas, he holds options\/stocks from Relmada Therapeutics (US) and NetraMark (Canada). M.R. is employed by University of Southern California and the Alzheimer\u2019s Therapeutics Research Institute (ATRI); received grants or contracts paid to his institution from Eisai (AHEAD study) and Eli Lilly (A4 study); received consulting fees from AC Immune and Ionis; and has participated on a data safety monitoring board or advisory board for Alzheon, Aptah Bio, Biohaven, Embic, Keystone Bio, Prescient Imaging and Positrigo. P.S. is employed by Life Science Partners and is professor emeritus Amsterdam University Medical Center; received grants or contracts paid to his institution from Novo Nordisk, Toyama, UCB, AC Immune and Alzheon; has an unpaid leadership position as chair of World Dementia Council and holds stock options in EQT AB. E.S. is employed by Acumen Pharmaceuticals; received consulting fees from Biogen, Cogstate, Cortexyme, Partner Therapeutics, Pinteon Therapeutics, Prothena, Vaccinex, Acumen, Pharmaceuticals, Gates Ventures LLC and Hoffman La Roche and payments were made to Siemers Integration LLC; participated on a data safety monitoring board for Hoffman La Roche; and has had a leadership or fiduciary role with the Alzheimer\u2019s Association and BrightFocus Foundation, both unpaid; holds stock options and is a shareholder for Acumen Pharmaceuticals, and is a shareholder for Eli Lilly and Company. H.S. is a full-time employee of the Alzheimer\u2019s Association, Chicago, has a spouse who is employed by Abbott Laboratories in an unrelated area, and has no financial conflicts to disclose. R.S. is employed by Brigham and Women\u2019s Hospital; received grants or contracts from the US NIA, Eli Lilly (public\u2013private partnership trial funding), Eisai (public\u2013private partnership trial funding), Alzheimer\u2019s Association and GHR Foundation; and received consulting fees from Abbvie, AC Immune, Acumen, Alector, Alnylam, Bristol-Myers Squibb, Cytox, Genentech, Ionis, Janssen, NervGen, Neuraly, Neurocentria, Oligomerix, Prothena, Roche, Shionogi and Vaxxinity. C.E.T. is employed by Amsterdam UMC; received grants or contracts for research from the European Commission (Marie Curie International Training Network, grant 86019, MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant 831434) EPND (IMI 2 Joint Undertaking, grant 101034344) and JPND (bPRIDE), National MS Society (Progressive MS Alliance), Alzheimer Drug Discovery Foundation, Alzheimer Association, Health Holland, the Dutch Research Council (ZonMW), including TAP-dementia, a ZonMw funded project (10510032120003) in the context of the Dutch National Dementia Strategy, Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands; is recipient of ABOARD, public\u2013private partnership receiving funding from ZonMW (73305095007) and Health\u2013Holland, Topsector Life Sciences & Health (PPP-allowance; LSHM20106); is a contract researcher for ADx Neurosciences, AC-Immune, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Siemens, Toyama, Vivoryon and the European Commission; received payment or honoraria to her institution from Eli Lilly, Grifols, Novo Nordisk, Olink and Roche; serves on editorial boards of <i>Medidact Neurologie<\/i>\/Springer and <i>Neurology: Neuroimmunology & Neuroinflammation<\/i>, and is editor of <i>Alzheimer Research and Therapy<\/i>. M.C. is a full-time employee of the Alzheimer\u2019s Association, has a daughter in the neuroscience program at the University of South Carolina, and has no financial conflicts to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}